July 1, 1996Annals of Internal Medicine
Anthracycline-Induced Cardiotoxicity
Why the study?
What is the clinical significance, detection, pathogenesis, and prevention of anthracycline-induced cardiotoxicity?
Population
Patients receiving anthracycline therapy, including childhood cancer survivors
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Supports vigilance for anthracycline cardiomyopathy in survivors; leaves open optimization of detection and cardioprotection strategies.
Structured PICO
What is the clinical significance, detection, pathogenesis, and prevention of anthracycline-induced cardiotoxicity?
P
Population
Patients receiving anthracycline therapy, including childhood cancer survivors
I
Intervention
Anthracycline therapy and cardioprotectants (e.g., dexrazoxane)
O
Outcome
Anthracycline-induced cardiotoxicity (cardiomyopathy, ventricular dysfunction)
Anthracycline-induced cardiotoxicity is a significant cause of morbidity and mortality in cancer survivors, highlighting the need for better detection and cardioprotection strategies.
Cite This Study
Shan et al. (1996) studied this question.